July 13, 2017
Owen McCarty, Ph.D. presented his research on “Factor XI and XII in Blood Clotting and Beyond: Contact Pathway Under Flow” at Wednesday’s State-of-the-Art Session
Read More
July 12, 2017
During Wednesday’s State-of-the-Art Session, Platelets Beyond Thrombosis, John W. Semple, Ph.D. highlighted the attributes of platelets and their precursor cells, megakaryocytes (MK) in their ability to modulate immunity, particularly via their major histocompatibility complex (MHC) class I molecules
Read More
July 12, 2017
In this State-of-the-Art Session entitled, “Neurobiology and Stroke-Stroke Models: Time for a Compromise”, Denis Vivien, M.D., Ph.D. discussed two stroke models being studied in his laboratory.
Read More
July 12, 2017
At Wednesday’s State-of-the-Art Session, “Platelets Beyond Thrombosis”, Wolfgang Bergmeier, Ph.D., presented ISTH attendees with a review of the literature on RAP1 signaling in platelets as well findings from his most recent research
Read More
July 12, 2017
Katerina Akassoglou, Ph.D. discussed with attendees at Wednesday’s State-of-the-Art Session her group’s research evaluating fibrin in neurological diseases
Read More
July 11, 2017
During Tuesday’s State-of-the-Art Session “Novel Therapies for Hemophilia”, President and Chief Scientific Officer of Spark Therapeutics, Katherine High, M.D., Ph.D. summarized findings from their phase I/II trial of the long-term safety and efficacy of factor IX (FIX) gene therapy in patients with hemophilia B
Read More